News about Global Pharma

Mochida Seeks Japan's Approval for Tocilizumab Biosimilar in Partnership with AYUMI

Mochida Seeks Japan's Approval for Tocilizumab Biosimilar in Partnership with AYUMI

This application is based on the results of a Phase I clinical study conducted in Japan with 110 healthy adults and a Phase III clinical study conducted in Japan with 368 patients with rheumatoid arthritis.

Global Pharma | 28/03/2025 | By Abha 992

Shree Ganesh Remedies Embraces Sustainability With 2 MW Solar Plant in Gujarat

Shree Ganesh Remedies Embraces Sustainability With 2 MW Solar Plant in Gujarat

Gujarat-based pharmaceutical company Shree Ganesh Remedies Ltd. has commissioned a 2 MW solar power plant in Gujarat, covering 70 percent of its power needs. The project is expected to generate annual savings of approximately INR 2 crore in electricity expenses.

Global Pharma | 27/03/2025 | By Manvi 320

Vasorum USA Receives FDA Approval for Celt ACD PLUS System with Blood Signal Technology

Vasorum USA Receives FDA Approval for Celt ACD PLUS System with Blood Signal Technology

This next-generation device enhances the proven Celt ACD platform by providing physicians with a visual indicator for precise placement and closure, particularly beneficial in cases where ultrasound imaging is not available.

Global Pharma | 27/03/2025 | By Manvi 248

aTyr Pharma Welcomes Dalia R. Rayes as Head of Commercial-Global Efzofitimod Franchise

aTyr Pharma Welcomes Dalia R. Rayes as Head of Commercial-Global Efzofitimod Franchise

Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches.

Global Pharma | 27/03/2025 | By Aishwarya 680

Department of Pharmaceuticals Organises Industry Dialogue on PRIP Scheme in Bengaluru

Department of Pharmaceuticals Organises Industry Dialogue on PRIP Scheme in Bengaluru

The session provided detailed insights into the PRIP Scheme, along with other government initiatives promoting and enabling research innovation in the sector.

Global Pharma | 27/03/2025 | By Aishwarya 360

Rarecells Appoints Dr. Neil Kurtz to its Board of Directors

Rarecells Appoints Dr. Neil Kurtz to its Board of Directors

Rarecells Inc. announces the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.

Global Pharma | 26/03/2025 | By Manvi 275

CDSCO Launches Digital Portal to Simplify Extension Process for Pharma MSMEs

CDSCO Launches Digital Portal to Simplify Extension Process for Pharma MSMEs

This initiative is integrated into the Online National Drugs Licensing System (ONDLS) and follows the Health Ministry's notification granting an extension for compliance with updated Good Manufacturing Practices (GMP).

Global Pharma | 26/03/2025 | By Aishwarya 510

Sense Diagnostics Appoints Gary Kurdziel as Chief Executive Officer, Effective from April 1, 2025

Sense Diagnostics Appoints Gary Kurdziel as Chief Executive Officer, Effective from April 1, 2025

Sense Diagnostics, Inc. announced that its board of directors has appointed Gary Kurdziel as Chief Executive Officer, effective April 1, 2025. Kurdziel, who most recently served as EVP and CCO for Sense Neuro Diagnostics, brings extensive global leadership experience spanning more than three decades in the medical device industry.

Global Pharma | 25/03/2025 | By Manvi 292

Oxford BioTherapeutics and Roche to Research on Novel Targets for Antibody-Based Therapeutics

Oxford BioTherapeutics and Roche to Research on Novel Targets for Antibody-Based Therapeutics

OBT’s recently launched enhanced proprietary OGAP®-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.

Global Pharma | 25/03/2025 | By Aishwarya 272

Syngene International to Procure Renewable Energy from O2 Power

Syngene International to Procure Renewable Energy from O2 Power

Syngene International Ltd., a Biocon subsidiary, will procure renewable energy from O2 Power’s 201.2 MW wind-solar hybrid plant in Karnataka under a captive arrangement. The company acquired 33.79 percent stake in the SPV for INR 6.5 crore.

Global Pharma | 25/03/2025 | By Manvi 437

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members